Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2007

View Archived Issues

Novel treatment options for cancer covered in recent patent literature

Snapshots in dermatology: The 16th EADV congress

Recent NeuroSearch and Memory patents describe novel antidepressants and antipsychotic agents

Soluble trimeric TRAIL shows promise for brain tumors

Long-term remission seen with MMX mesalamine in ulcerative colitis

Survivin-2B peptide vaccine evaluated in phase I urothelial cancer study

Recent Biogen patent discloses novel therapeutic agents for fibrosis and related disorders

Fast track designation for CellCept in treatment of lupus nephritis

Enrollment open in phase III study of Labopharm's once-daily trazodone

Phase I study begins for AIR parathyroid hormone

BioLineRx files to begin European pilot study of BL-1040

Series B financing to support phase I testing of PNP's cancer technology

New phase II trial studies Surfaxin for pediatric acute respiratory failure

Viread noninferior to Hepsera in HBeAg-negative/anti-HBe positive subjects

Nebido maintains clinically therapeutic testosterone levels in hypogonadal men

MK-0974 significantly improves migraine pain relief two hours postdosing

Albuferon shows comparable efficacy to Pegasys with better quality of life

Zonisamide SR shows improved tolerability over zonisamide IR

FDA and Nuvo discuss Pennsaid approvable letter

BioMS synthetic peptide enters U.S. phase III trial for multiple sclerosis

Fast track designation for tamibarotene in acute promyelocytic leukemia

Japanese orphan drug designation for Naglazyme

Priority review for Erbitux sBLA in metastatic colorectal cancer

Celecox launched in Japan

Japanese launch for imidafenacin for overactive bladder

Alvesco launched in Japan for bronchial asthma

Tracleer approved in E.U. to reduce digital ulcers in systemic sclerosis patients

KOS-1584: Phase I to continue with a 3-hour infusion regimen only

VX-001 elicits immune response, prolongs TTP and overall survival in NSCLC patients

Dosing schedule chosen for future trials of R-1507

Phase I/II trial of SPC-2996 shows benefits in advanced CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...